Market Trends JNJ met main goal in late-stage trial for ulcerative colitis treatment (JNJ:NYSE)By admin8996erT0allFebruary 21, 2025 Rasi BhadramaniJohnson & Johnson (JNJ) said on Friday that its late-stage study of TREMFYA as an induction therapy for adults…
